OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Simon Ducharme

1 Projects | 1 Researchers | $1,399,078 Invested

2021

McGill University

Simon Ducharme, MD, MSc, FRCPC

Open-label Clinical Trial of Nabilone for Neuropsychiatric Symptoms in Frontotemporal Dementia

  • Funding Amount: $1,399,078
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Active